TrialAnnals of the rheumatic diseases2018

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.

Nicolino Ruperto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.